Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06428643 · ClinicalTrials.gov registry record · NA
A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities
A NA study, sponsored by Tulane University.
- Recruiting
- Registry status
- NA
- Development phase
- 2,322
- Enrollment target
NCT06428643: Recruiting NA study, sponsored by Tulane University.
NCT06428643 is a NA study that is actively recruiting participants, run by Tulane University. The registered enrollment target is 2,322 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06428643, a NA study, is actively recruiting participants, sponsored by Tulane University.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,322 participants
- Enrollment target
Study Summary
This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.
Primary Outcome
Primary outcome
Interventions
- OTHER Chlamydia, gonorrhea, syphilis, and HIV screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,322 participants |
| Start Date | 2025-08-14 |
| Est. Completion | 2029-09-01 |
| Phase | NA |
What NCT06428643 shows while recruiting
NCT06428643 is an interventional study that assigns participants to a tested intervention. Its 2,322 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 1 intervention - of which Chlamydia, gonorrhea, syphilis, and HIV screening is the first listed.
NCT06428643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06428643 about?
NCT06428643 is a clinical study titled "A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities". This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened...
What is the current status of trial NCT06428643?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,322 participants. The study started on 2025-08-14. Estimated completion is 2029-09-01.
What interventions are being tested in trial NCT06428643?
The interventions under investigation include: Chlamydia, gonorrhea, syphilis, and HIV screening (OTHER).
Who is sponsoring clinical trial NCT06428643?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06428643's enrollment target sits among peer trials
2,322 46th of 2000 higher than 1,955 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05700760 · 2,320 participants · NA
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
- NCT06824194 · 2,320 participants · Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- NCT06679140 · 2,330 participants · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI